Low-Dose Tenecteplase vs Standard-Dose Alteplase for Acute Ischaemic Stroke: An Imaging Based Safety and Efficacy Study

点击翻译按钮获取中文摘要

This study compares standard dose alteplase (a proven stroke thrombolytic) with a low dose of the new medication tenecteplase for stroke treatment. We propose that the clot-dissolving activity of low-dose tenecteplase will be superior to alteplase, with a lower risk of brain bleeding. MRI scanning is the most effective way of assessing outcomes and will be used to measure how well the medication restores blood flow, the amount of permanent brain damage, and whether any brain bleeding occurs.